Phase 2 study with BAY63-2521 in PH associated with IIP

• Research type

  Research Study

• Full title

  A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP)

• IRAS ID

  151042

• Contact name

  John Wort

• Contact email

  S.Wort@rbht.nhs.uk

• Sponsor organisation

  Bayer Public Limited Company

• Eudract number

  2010-024332-42

• ISRCTN Number

  ISRCTN

• Research summary

  Efficacy and safety of riociguat in patients with symptomatic pulmonary hypertension (PH) associated with idiopathic interstitial pneumonias (IIP).

• REC name

  London - Brent Research Ethics Committee

• REC reference

  14/LO/0699

• Date of REC Opinion

  2 Jun 2014

• REC opinion

  Favourable Opinion